Critique Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indicator: Together with chemotherapy, to the therapy of adult clients with locally recurrent unresectable or metastatic triple-damaging breast most cancers which have not acquired prior chemotherapy for metastatic ailment and whose tumours Specific programmed cell death-ligand